Related references
Note: Only part of the references are listed.Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma
Tyler R. Simpson et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Standards of care for treatment of recurrent glioblastoma-are we there yet?
Michael Weller et al.
NEURO-ONCOLOGY (2013)
A balance of interleukin-12 and-23 in cancer
Shin Foong Ngiow et al.
TRENDS IN IMMUNOLOGY (2013)
Anti-CTLA-4 Antibodies of IgG2a Isotype Enhance Antitumor Activity through Reduction of Intratumoral Regulatory T Cells
Mark J. Selby et al.
CANCER IMMUNOLOGY RESEARCH (2013)
Sequential Immunotherapy by Vaccination With GM-CSF-expressing Glioma Cells and CTLA-4 Blockade Effectively Treats Established Murine Intracranial Tumors
Pankaj Agarwalla et al.
JOURNAL OF IMMUNOTHERAPY (2012)
Inhibition of IL-12/IL-23 signaling reduces Alzheimer's disease-like pathology and cognitive decline
Johannes vom Berg et al.
NATURE MEDICINE (2012)
IL-15 Regulates Homeostasis and Terminal Maturation of NKT Cells
Laura E. Gordy et al.
JOURNAL OF IMMUNOLOGY (2011)
The emerging role of CTLA4 as a cell-extrinsic regulator of T cell responses
Lucy S. K. Walker et al.
NATURE REVIEWS IMMUNOLOGY (2011)
Mouse models for melanoma: a personal perspective
Juergen C. Becker et al.
EXPERIMENTAL DERMATOLOGY (2010)
Prognostic significance and mechanism of Treg infiltration in human brain tumors
Joannes F. M. Jacobs et al.
JOURNAL OF NEUROIMMUNOLOGY (2010)
IL-12 initiates tumor rejection via lymphoid tissue-inducer cells bearing the natural cytotoxicity receptor NKp46
Maya Eisenring et al.
NATURE IMMUNOLOGY (2010)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Intracerebral Interleukin 12 Induces Glioma Rejection in the Brain Predominantly by CD8(+) T Cells and Independently of Interferon-gamma
Marcus Vetter et al.
JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY (2009)
Glioma immunotherapy by IL-21 gene-modified cells or by recombinant IL-21 involves antibody responses
Antonio Daga et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
CD4+FoxP3+regulatory T cells gradually accumulate in gliomas during tumor growth and efficiently suppress antiglioma immune responses in vivo
Oliver M. Grauer et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Systemic CTLA-4 blockade ameliorates glioma-induced changes to the CD4(+) T cell compartment without affecting regulatory T-cell function
Peter E. Fecci et al.
CLINICAL CANCER RESEARCH (2007)
Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells
Jinwei Hu et al.
CANCER RESEARCH (2006)
IL-23 promotes tumour incidence and growth
John L. Langowski et al.
NATURE (2006)
Detailed characterization of the mouse glioma 261 tumor model for experimental glioblastoma therapy
Tunde Szatmari et al.
CANCER SCIENCE (2006)
Interleukin-23-expressing bone marrow-derived neural stem-like cells exhibit antitumor activity against intracranial glioma
XP Yuan et al.
CANCER RESEARCH (2006)
SD-208, a novel transforming growth factor β receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo
M Uhl et al.
CANCER RESEARCH (2004)
Induction of an antitumor immunological response by an intratumoral injection of dendritic cells pulsed with genetically engineered Semliki Forest virus to produce interleukin-18 combined with the systemic administration of interleukin-12
R Yamanaka et al.
JOURNAL OF NEUROSURGERY (2003)
Antitumor and antimetastatic activity of IL-23
CH Lo et al.
JOURNAL OF IMMUNOLOGY (2003)
Marked enhancement of antitumor immune responses in mouse brain tumor models by genetically modified dendritic cells producing Semliki Forest virus-mediated interleukin-12
R Yamanaka et al.
JOURNAL OF NEUROSURGERY (2002)
Interleukin-12 in anti-tumor immunity and immunotherapy
MP Colombo et al.
CYTOKINE & GROWTH FACTOR REVIEWS (2002)
Share Paper
